io9 published data in the Journal of Clinical Oncology today demonstrating that its AI biomarker platform OncoGaze identified HRD-positive patients from routine tissue slides

blonca9
Jul 31, 2024
1 min read

CEO Greg Hamilton describes how patients who were diagnosed with this software platform had better outcomes, how it might increase the treatable patient population, and next steps towards applying for approval as a companion diagnostic for PARP inhibitors.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

io9 published data in the Journal of Clinical Oncology today demonstrating that its AI biomarker platform OncoGaze identified HRD-positive patients from routine tissue slides

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight